Ionis (IONS) Price Target Hiked Following Positive Zilganersen Trial Results

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) ranks among the best biotech stocks to buy. On September 24, Leerink Partners maintained its Outperform rating on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and raised its price target from $63 to $68. The boost comes after topline results for Ionis’ Alexander disease therapy, zilganersen.

Using the 10-meter walk test (10MWT), Leerink observed that Zilganersen showed a statistically significant improvement in stabilizing gait speed and steady gains across key secondary endpoints. The company’s valuation methodology for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) now includes a market model for Alexander disease.

While open-label extension data, though still years away, will offer more information about the treatment’s effect on life expectancy and disease progression, detailed results from the Zilganersen trial are anticipated at an upcoming medical conference.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) produces medications for serious medical conditions, with a specific emphasis on cardiovascular and neurological disorders.

While we acknowledge the potential of IONS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IONS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.